18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma

Cancer

Volumn 117, Issue 20, 2011, Pages 4779-4787

  Kim, Beom Kyung ^a   Kang, Won Jun ^a   Kim, Ja Kyung ^a   Seong, Jinsil ^a,b   Park, Jun Yong ^a   Kim, Do Young ^a   Ahn, Sang Hoon ^a   Lee, Do Youn ^a   Lee, Kwang Hoon ^a   Lee, Jong Doo ^a,b   Han, Kwang Hyub ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Brain Korea   (South Korea)

Author keywords

chemoradiotherapy; fluorodeoxyglucose; hepatocellular carcinoma; standardized uptake value; survival; tumor response

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER MORTALITY; CHEMORADIOTHERAPY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIOACTIVITY; RISK ASSESSMENT; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR GROWTH; ANALYSIS OF VARIANCE; BLOOD; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; HEPATIC ARTERY; INTRAARTERIAL DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; RADIATION DOSE; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; CARCINOMA, HEPATOCELLULAR; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 80053916741     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26099     Document Type: Article

References (37)

1. Pisani P, Ferlay J, Bray F, Parkin DM,. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108. (Pubitemid 40372904)
2. El-Serag HB, Rudolph KL,. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132: 2557-2576. (Pubitemid 46890874)
3. Llovet JM, Burroughs A, Bruix J,. Hepatocellular carcinoma. Lancet. 2003; 362: 1907-1917. (Pubitemid 37518510)
4. Sherman M, Bruix J,. Management of hepatocellular carcinoma. Hepatology. 2005; 42: 1208-1236. (Pubitemid 43112690)
5. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.
6. Zhu AX, Clark JW,. Commentary: sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy. Oncologist. 2009; 14: 67-69.
7. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
8. Hawkins MA, Dawson LA,. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer. 2006; 106: 1653-1663.
9. Han K, Seong J, Kim JK, Ahn SH, Lee DY, Chon CY,. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer. 2008; 113: 995-1003.
10. Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005; 23: 8739-8747. (Pubitemid 46211519)
11. Koom WS, Seong J, Han KH, Lee DY, Lee JT,. Is local radiotherapy still valuable for patients with multiple intrahepatic hepatocellular carcinomas? Int J Radiat Oncol Biol Phys. 2010; 77: 1433-1440.
12. Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med. 1996; 23: 1641-1674.
13. Siemerink EJ, Mulder NH, Brouwers AH, Hospers GA,. 18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma. Oncologist. 2008; 13: 734-735; author reply 736. (Pubitemid 351904919)
14. Seo S, Hatano E, Higashi T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 2007; 13: 427-433. (Pubitemid 46225346)
15. Lee JW, Paeng JC, Kang KW, et al. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med. 2009; 50: 682-687.
16. Hatano E, Ikai I, Higashi T, et al. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg. 2006; 30: 1736-1741. (Pubitemid 44411232)
17. Kornberg A, Freesmeyer M, Barthel E, et al. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant. 2009; 9: 592-600.
18. Higashi T, Hatano E, Ikai I, et al. FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2010; 37: 468-482.
19. Kornberg A, Kupper B, Thrum K, et al. Increased 18F-FDG uptake of hepatocellular carcinoma on positron emission tomography independently predicts tumor recurrence in liver transplant patients. Transplant Proc. 2009; 41: 2561-2563.
20. Korean Liver Cancer Study Group and National Cancer Center. Practice guidelines for management of hepatocellular carcinoma 2009 [in Korean]. Korean J Hepatol. 2009; 15: 391-423.
21. Ueno S, Tanabe G, Nuruki K, et al. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res. 2002; 24: 395-403. (Pubitemid 36002129)
22. Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006; 44: 723-731.
23. Gwyther SG, Christian MC, van Oosterom AT, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
24. Flier JS, Mueckler MM, Usher P, Lodish HF,. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science. 1987; 235: 1492-1495. (Pubitemid 17038084)
25. Okazumi S, Isono K, Enomoto K, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med. 1992; 33: 333-339.
26. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med. 1995; 36: 1811-1817.
27. Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999; 94: 3314-3319.
28. Yoon KT, Kim JK, Kim do Y, et al. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Oncology. 2007; 72 (suppl 1): 104-110. (Pubitemid 350256673)
29. Ledoux S, Yang R, Friedlander G, Laouari D,. Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res. 2003; 63: 7284-7290. (Pubitemid 37413469)
30. Burk D, Woods M, Hunter J,. On the significance of glucolysis for cancer growth, with special reference to Morris rat hepatomas. J Natl Cancer Inst. 1967; 38: 839-863.
31. Medina RA, Owen GI,. Glucose transporters: expression, regulation and cancer. Biol Res. 2002; 35: 9-26. (Pubitemid 34661867)
32. Kim BK, Han KH, Park YN, et al. Prediction of microvascular invasion before curative resection of hepatocellular carcinoma. J Surg Oncol. 2008; 97: 246-252.
33. Vauthey J, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002; 20: 1527-1536. (Pubitemid 34260532)
34. Zhao JD, Liu J, Ren ZG, et al. Maintenance of sorafenib following combined therapy of 3-dimensional conformal radiation therapy/intensity- modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study. Radiat Oncol. 2010; 5: 12-18.
35. Chi KH, Liao CS, Chang CC, et al. Angiogenic blockade and radiotherapy in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2010; 78: 188-193.
36. Cheng JC, Chou CH, Kuo ML, Hsieh CY,. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene. 2006; 25: 7009-7018. (Pubitemid 44722069)
37. Chung YL, Jian JJ, Cheng SH, et al. Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma. Clin Cancer Res. 2006; 12: 2706-2715.